Orexo AB
ORXOF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.31M
Close$
$1.22
121.6% upside
Current Fair Value
121.6% upsideUndervalued by 121.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $19.31 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-3.74 |
| Beta | 0.89 |
| Outstanding Shares | 35,126,410 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.75 |
|---|---|
| PEG | -0.33 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
October 22, 2026
EPS Estimate
$-0.21
Consensus analyst estimateRevenue Estimate
$447,750
Consensus analyst estimateNext Earnings Call
Expected Date
February 4, 2027
EPS Estimate
$-0.19
Consensus analyst estimateRevenue Estimate
$600,600
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Orexo AB
65 employees
CEO: Nikolaj Sorensen
Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United St...